Upstream Bio, Inc. (NASDAQ:UPB) Director Buys $14,025,000.00 in Stock

Upstream Bio, Inc. (NASDAQ:UPB) Director Erez Chimovits bought 825,000 shares of Upstream Bio stock in a transaction dated Tuesday, October 15th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $14,025,000.00. Following the completion of the purchase, the director now directly owns 4,554,873 shares of the company’s stock, valued at approximately $77,432,841. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Upstream Bio Trading Down 0.1 %

UPB traded down $0.03 during trading on Thursday, reaching $23.60. The stock had a trading volume of 420,713 shares, compared to its average volume of 479,653. Upstream Bio, Inc. has a one year low of $20.74 and a one year high of $24.35.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.